Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-12-05
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 75
- Registration Number
- NCT00073723
- Locations
- πΊπΈ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)
- Conditions
- First Posted Date
- 2003-11-13
- Last Posted Date
- 2006-12-19
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT00072722
- Locations
- πΊπΈ
University of Colorado Health Science Center, Denver, Colorado, United States
πΊπΈBaylor College of Medicine, Houston, Texas, United States
A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
- Conditions
- Interventions
- First Posted Date
- 2003-11-05
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Celgene
- Target Recruit Count
- 358
- Registration Number
- NCT00071799
- Locations
- πͺπΈ
Hospital de Leon, Leon, Spain
π΅π±Samodzielny Publiczny Szpital Kliniczny, Lublin, Poland
π¦πΊThe Royal Perth Hospital, Perth, Western Australia, Australia
A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)
- First Posted Date
- 2003-08-27
- Last Posted Date
- 2008-01-03
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT00067743
- Locations
- πΊπΈ
Swedish Pain Management, Seattle, Washington, United States
πΊπΈUNC Hospitals University of North Carolina, Chapel Hill, North Carolina, United States
πΊπΈDrexel University College of Medicine, Philadelphia, Pennsylvania, United States
Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2003-07-23
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 222
- Registration Number
- NCT00065351
- Locations
- πΊπΈ
Providence St. Joseph Medical Center/Cancer Center, Burbank, California, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality
- First Posted Date
- 2003-07-18
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 148
- Registration Number
- NCT00065156
- Locations
- πΊπΈ
Arizona Cancer Center, Tucson, Arizona, United States
πΊπΈDesert Hematology & Oncology Medical Group, Rancho Mirage, California, United States
πΊπΈMayo Clinic, Rochester, Minnesota, United States
Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes
- First Posted Date
- 2003-07-17
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 215
- Registration Number
- NCT00064974
- Locations
- πΊπΈ
Alta Bates Cancer Center, Berkeley, California, United States
πΊπΈMidwest Cancer Research Group, Skokie, Illinois, United States
πΊπΈThe Cleveland Clinic Foundation, Cleveland, Ohio, United States
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2003-04-08
- Last Posted Date
- 2015-09-11
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 470
- Registration Number
- NCT00057564
- Locations
- πΊπΈ
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
πΊπΈClinical Research Consultants, Inc., Hoover, Alabama, United States
πΊπΈArizona Clinical Research Center, Tucson, Arizona, United States
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
- Conditions
- First Posted Date
- 2003-04-08
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 274
- Registration Number
- NCT00057616
- Locations
- π¦πΊ
Royal Newcastle Hospital, Newcastle, New South Wales, Australia
π¦πΊWestmead Hospital, Westmead, New South Wales, Australia
π¦πΊRoyal Hobart Hospital, Hobart, Tasmania, Australia
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 353
- Registration Number
- NCT00056160
- Locations
- πΊπΈ
Ohio State University, Columbus, Ohio, United States
πΊπΈMD Anderson Cancer Center, Houston, Texas, United States
πΊπΈClinical Research Consultants, Inc., Hoover, Alabama, United States